Mark Plavsic - 02 Mar 2026 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role: Chief Technology Officer
Signature: /s/ Conor Kilroy, as Attorney-in-Fact
Issuer symbol: AURA
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2026, 16:05:55 UTC
Previous filing: 17 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Plavsic Mark	Chief Technology Officer	C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON	/s/ Conor Kilroy, as Attorney-in-Fact	03 Mar 2026	0001868719

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AURA	Common Stock	Award	$0	+62,339	+34%	$0.000000	243,736	02 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AURA	Stock Option (Right to Buy)	Award	$0	+112,661		$0.000000	112,661	02 Mar 2026	Common Stock	112,661	$6.14	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
F2	The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.